Cancer Genetics Laboratory

The Cancer Genetics Laboratory studies cancers of endocrine organs, many of which develop as a result of hereditary syndromes.

Our research team has expertise in cancer biology, diagnostic genetic testing, family counselling and targeted surveillance programs.

Our research translates discoveries in genetic research to improved clinical care for patients with endocrine cancers.


Professor Rory Clifton-Bligh  Professor Roderick Clifton-Bligh


Head, Cancer Genetics Laboratory
Head, Department of Endocrinology, Royal North Shore Hospital

team-Bruce-Robinson Professor Bruce Robinson

Co-Head, Cancer Genetics Laboratory

Dr Stan Sidhu Professor Stan Sidhu

Co-Head, Cancer Genetics Laboratory

Dr Diana (Dindy) Benn PhD

Senior Research Scientist

Dr Martyn Bullock PhD

Postdoctoral Scientist

Dr Catherine Luxford PhD

Laboratory Manager







Dr Ying Zhu - Hospital Scientist

Rozelle Harvie - Research Assistant

Marthe Chehade - PhD Student

Dr Amanda Seabrook - PhD Student

Dr Ayanthi Wijewardene - PhD Student

Dr Dahlia Davidoff - PhD Student

Dr Christopher Muir - PhD Student

Nanette Lacson - Clinical Trials Manager

Sumathy Perampalam - PhD Student

Adwoa Sey - Research Scientist

Shejil Kumar - PhD Student

Eleanor White - PhD Student

Linh Nguyen - PhD Student 

Eline Jager - Visiting Research Student 

Liza Nery - Clinical Research Manager

Benjamin Decooman - Visiting Student

Anika Humaira - Research Placement Student

Annabelle Hayes - PhD Student

Our current research programs are:

Cancer Genetics Diagnostic Laboratory

We perform NATA-accredited genetic testing for Multiple Endocrine Neoplasia syndrome type 2, Hereditary Phaeochromocytoma/Paraganglioma syndromes, hereditary hyperparathyroidism disorders and hereditary thyroid disorders.

Phaeochromocytoma/Paraganglioma syndromes

Studying hereditary mutations in key genes associated with phaeochromocytomas and paragangliomas. Our research has made several discoveries that link mitochondrial dysfunction with a predisposition to these and other cancers. These biomarker discoveries have been translated into routine pathology practice.

Thyroid Cancer

Studying tumour or hereditary DNA mutations that predispose people to thyroid cancers. Our ground breaking work has included discovery of fusion chromosomes in particular subtypes of thyroid cancer. It has also examined the role of the BRAF oncogene in cancer metastasis and the specific role of a thyroid developmental transcription factor FOXE1 with thyroid cancer predisposition, a finding that links disruption in an early developmental gene with cancer development in adult life.

Adrenal Cancer

In this program, we study the microRNA changes associated with the highly malignant cancer of the adrenal cortex.

Pituitary Tumours

Studying the genetic and epigenetic changes of pituitary neoplasms.

Events, News and Seminars

Improving cancer detection in young people with neurofibromatosis type 1

Improving cancer detection in young people with neurofibromatosis type 1

Researchers from Royal North Shore Hospital and the Kolling Institute will lead Australia’s first st..... Read more

Category: New Treatment, Research Excellence

Celebrating the quiet achievers behind our clinical trial success

Celebrating the quiet achievers behind our clinical trial success

International Clinical Trials Day provided the chance to recognise the many people contributing to o..... Read more

Category: New Treatment, Research Excellence

Kolling Institute Newsletter May 2025